EI
MLYS icon

EAM Investors’s Mineralys Therapeutics MLYS Stock Holding History

EAM Investors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-96,135
Closed -$3.49M – 343
2025
Q4 		$3.49M Sell
96,135
-31,412
-25% -$1.26M 0.39% 135
2025
Q3 		$4.76M Buy
+127,547
New +$2.76M 0.55% 70
2025
Q2 		– Sell
-164,273
Closed -$2.61M – 311
2025
Q1 		$2.61M Buy
+164,273
New +$1.89M 0.45% 114

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

EAM Investors's MLYS Position: Q1 2026 in Review

EAM Investors sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 96,135 shares — an estimated $3.49M sold.

EAM Investors first reported a position in MLYS in Q1 2025 and held it in 3 quarters. The position peaked at $4.76M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • EAM Investors reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EAM Investors sold 96,135 Mineralys Therapeutics shares in Q1 2026, an estimated $3.49M.
  • EAM Investors first reported a position in Mineralys Therapeutics in Q1 2025 and held it in 3 quarters.
  • EAM Investors's Mineralys Therapeutics position peaked at $4.76M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.